Is CIRS a Real Diagnosis? What the Peer-Reviewed Evidence Shows

Yes. CIRS (Chronic Inflammatory Response Syndrome) has two randomized controlled trials, validated biomarkers orderable at LabCorp, a published case definition, gene expression data in one subgroup (CIRS-Ciguatera) so distinct that a machine learning algorithm classified those patients with 100% accuracy, and reversible brain changes documented on FDA-cleared imaging. A 2024 systematic review found more published treatment evidence for CIRS than exists for ME/CFS, which the CDC already recognizes.

So why do critics still call it "fabricated"? Because they're responding to the wellness-industry version of mold illness (unvalidated urine tests, dubious home kits, influencer diagnoses) and never engaging with the peer-reviewed clinical framework. That gap between evidence and acceptance is the real story here.

We walk through what the published literature actually says below and take the strongest counterarguments head-on. If you want to explore whether mold-related illness may be contributing to your symptoms, MoldCo Care can help you work through the evaluation, if we're available in your state.

Key findings at a glance

• A 2024 systematic review identified 13 peer-reviewed articles comprising 14 studies on CIRS treatment, including two randomized controlled trials
• A double-blind, placebo-controlled trial showed treatment outperformed placebo with p=0.012 (placebo group: p>0.999)
• In CIRS-Ciguatera patients, gene expression analysis achieved 100% classification accuracy separating them from healthy controls using machine learning (this applies to that subgroup, not CIRS broadly)
• 112 of 114 epidemiological studies (98.2%) found adverse health effects from indoor mold and dampness exposure
• FDA-cleared MRI software documented reversible brain volume changes in CIRS patients that trended toward normal after treatment
• The U.S. Government Accountability Office independently published a case definition paralleling published CIRS criteria in 2008

What the "fabricated" label actually costs

"It's been a journey even talking publicly about mold illness since it sounds like quackery. Getting help has been even harder. Most doctors downplay the impact of mold." MoldCo patient

That's not an isolated experience. People with CIRS are commonly misdiagnosed with fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome (IBS), anxiety, depression, or somatoform disorders. When the diagnosis itself is called fake, patients don't just lose access to treatment. They lose credibility with their own doctors. They stop trusting their own bodies.

One Reddit user living in a mold-contaminated home described severe neurological symptoms: "My brain feels damaged and swollen... Someone has suggested that I do therapy because how bad it all is, but I just don't see how that could be helpful as I can't even have a rational thought." That's neuroinflammation being mislabeled as a psychiatric problem. It happens because the underlying condition isn't taken seriously.

The question "is CIRS real?" isn't abstract. It determines whether people get help or get dismissed.

What CIRS actually is (a 60-second primer)

CIRS stands for Chronic Inflammatory Response Syndrome. Here's the short version:

1. A genetically susceptible person (about 24% of the population carries the relevant HLA-DR/DQ genes) gets exposed to biotoxins, usually from a water-damaged building
2. Their immune system can't clear the toxins through normal pathways
3. This triggers a chronic inflammatory cascade across multiple body systems
4. The result is a measurable pattern of immune dysregulation: elevated inflammatory markers (TGF-beta1, C4a, MMP-9) and suppressed regulatory ones (MSH, VIP)

In plain English: some people's immune systems get stuck in "fight mode" after mold exposure, and we can measure that with standard blood tests. This isn't a proprietary panel or a fringe lab. These are biomarkers orderable through national laboratories like LabCorp.

The evidence

The 2024 systematic review

In 2024, Dooley, Vukelic, and Jim published a systematic review in Annals of Medicine & Surgery examining the clinical evidence for CIRS treatment. They found 13 peer-reviewed articles comprising 14 studies, including two randomized controlled trials (Level II evidence).

The Shoemaker Protocol was the only treatment in the published literature with documented clinical efficacy for CIRS.

What matters here for the "fabricated" question: the review included independent confirmation from researchers outside the original group (Conti, Harding, Nordin, Ratnesselan). One common criticism of CIRS research is that it's too self-referential. The systematic review shows it isn't.

And here's the comparison that frames this whole article. ME/CFS, which the CDC officially recognizes, lacks a defined etiology, biomarkers, or a treatment protocol that reverses the underlying conditions. CIRS has all three.

The RCT

The strongest single piece of evidence is a double-blind, placebo-controlled crossover trial from Shoemaker and House, published in Neurotoxicology and Teratology in 2006. The cholestyramine treatment group showed statistically significant improvement (p=0.012). The placebo group showed none (p>0.999).

That's the same study design we require for FDA drug approvals. Fabricated conditions don't produce statistically significant separations from placebo in double-blind trials.

A formal CIRS case definition was published separately by Shoemaker in a 2006 book chapter (in Eckhardt Johanning's Bioaerosols, Fungi, Bacteria, Mycotoxins and Human Health) and refined in the Shoemaker, Mark, and McMahon 2010 Policyholders of America consensus. It requires documented exposure, symptoms in at least 4 of 8 organ systems, and abnormalities in at least 3 of 6 objective laboratory parameters. That's not a vague symptom checklist. It's a multi-system diagnostic framework with objective measurability built in.

You can't fake your transcriptome

If CIRS were fabricated, you wouldn't expect it to leave a molecular fingerprint. But a 2015 study in BMC Medical Genomics by Ryan, Wu, and Shoemaker found exactly that in CIRS-Ciguatera patients. Analyzing gene expression profiles versus healthy controls, and using support vector machine classification (a machine learning method), they separated cases from controls with 100% accuracy. At low stringency (p<0.05, fold change >1.4) 185 genes were differentially expressed; at high stringency (p<0.01, fold change >1.5) 55 genes were.

You can argue about symptoms. You can argue about case definitions. It's harder to argue with a differentially expressed gene set that a blind algorithm sorts perfectly.

A few important caveats. This was a single CIRS subtype (post-Ciguatera), so the result doesn't extend automatically to every CIRS patient. Gene expression analysis isn't a general diagnostic test. What it demonstrates is that at least some forms of CIRS leave a measurable molecular signature, which is not what you'd expect from a "fabricated" condition.

Brain imaging on an FDA-cleared scan

A 2016 prospective study by McMahon, Shoemaker, and Ryan used NeuroQuant, an FDA-cleared MRI analysis tool. The IRB-approved study (n=91: 28 untreated CIRS patients, 40 treated, 23 matched controls) found statistically significant differences in brain volume between CIRS patients and controls.

After treatment, brain volumes trended toward control levels.

Forebrain swelling visible on FDA-cleared imaging doesn't come from a made-up diagnosis. And it doesn't reverse with a specific treatment protocol unless something real is happening in the brain.

"Exposed to high levels of toxic mold for months in a rental home. Brain fog, fatigue, sick more often, working memory clobbered. Treatment with MoldCo has been a huge blessing... If not for them mold wouldn't even be on my radar as a potential cause. Most doctors aren't trained to diagnose it." MoldCo patient

Wondering if mold-related illness might explain your symptoms? MoldCo connects you with providers who can help you work through the evaluation. Start your evaluation to get clarity on whether mold could be a factor, if available in your state.

98.2% epidemiological concordance

Beyond clinical trials, the epidemiological picture points in one direction. A large-scale review by Dooley and McMahon in Internal Medicine Review (2020) examined 114 epidemiological studies on mold exposure and health effects. 112 of 114 (98.2%) identified a correlation between chronic indoor microbial growth or dampness exposure and adverse health effects. 79 of those studies showed statistically significant results with odds ratios or relative risks of 2.0 or higher.

Health effects spanned respiratory, neurological, immunologic, cognitive, ophthalmologic, dermatologic, gastrointestinal, and musculoskeletal systems. That's not a narrow finding.

Independent replication is growing

A common objection is that CIRS research comes from one group. This was partly true in the early years and even the early decades. It's less true now.

Harding et al. at CUNY (City University of New York) conducted an independent animal model study showing that both toxic and non-toxic mold spores caused innate immune activation, along with measurable neural and cognitive dysfunction as well as emotional changes. This came from an independent academic institution, not Shoemaker's research group.

Bredesen's 2016 study on inhalational Alzheimer's identified a subtype he attributed to CIRS pathology. That same year, Gunn et al. linked biotoxin illness to inflammatory bowel disease in a separate line of research. Beyond these, there are dozens of neurocognitive-dysfunction studies from groups outside the original Shoemaker team.

McMahon's 2017 study evaluated 1,061 consecutive patients, the largest published cohort for CIRS. Diagnostic accuracy showed alpha error rates as low as 1.10 x 10^-6 for the combined age groups of 0 to 10.9 years. A separate 2024 biomarker study used progressive biomarker panels (from initial screening through transcriptomics) to differentiate CIRS from ME/CFS, reinforcing that CIRS has defined biomarkers where ME/CFS doesn't.

The evidence base is growing, and it's growing beyond any single research team.

Taking on the strongest counterarguments

We're not interested in straw men. These are the two most prominent critiques, and we think they both get something right and something wrong.

"CIRS is a fabricated pseudoscience diagnosis"

This critique, most publicly made by immunologist Andrea Love in Skeptical Inquirer and on social media, makes valid points. Urine mycotoxin tests aren't validated. At-home mold test kits are unreliable. Wellness influencers make irresponsible claims about "toxic mold." We agree with all of that.

But Love's critique targets the wellness-industry version of mold illness and never engages with the peer-reviewed clinical framework. She cites a 3% mold allergy prevalence figure, which is accurate for IgE-mediated allergic response. CIRS isn't an allergic response. It's innate immune dysfunction, a completely different pathway. The 3% number is the wrong statistic for this condition.

What Love doesn't address: the 2024 systematic review with 14 studies and 2 RCTs. The 100% transcriptomic classification accuracy. The reversible brain volume changes on FDA-cleared imaging. The 98.2% epidemiological concordance across 114 studies. The evidence-based sequential treatment protocol with documented clinical efficacy.

Criticizing urine mycotoxin tests and then concluding that CIRS is fabricated is like criticizing horoscopes and then concluding that astronomy is fake. The junk science is real. The published clinical research is also real. They're not the same thing.

"CIRS isn't an established medical diagnosis"

UCLA Health published this framing in an "Ask the Doctors" Q&A column. The piece accurately notes that CIRS lacks mainstream consensus. But it doesn't engage with the systematic review evidence, the RCTs, or the published case definitions.

There's a distinction worth making. Institutional adoption is a social process driven by funding cycles, training infrastructure, curricular inertia, and the professional cost of being early on a contested diagnosis. Scientific evidence is what gets published in peer-reviewed journals with replicable methodology and statistical significance. CIRS has the latter. It doesn't yet have the former.

We're honest about that gap. CIRS doesn't have a dedicated ICD-10 code yet. Most practicing clinicians who treat it bill under Z77.120 (contact with and suspected exposure to mold), which is more accurate than the older R65.10 SIRS code and better describes what's actually being evaluated. Most medical schools don't teach CIRS. Most primary care doctors haven't heard of it. The ACMT's 2025 position statement on mold-related inhalation exposures shows how professional bodies are engaging with the evidence, but broad institutional recognition hasn't happened yet.

"Not yet mainstream" and "fabricated" are very different claims. The evidence exists. The institutional infrastructure hasn't caught up.

What we're not claiming

Credibility requires honesty about limitations.

CIRS isn't universally accepted. We just showed you the evidence exists. We're not pretending the medical establishment has embraced it. Over 40 peer-reviewed articles cover CIRS diagnosis, treatment, imaging, biomarkers, and transcriptomics, including 13 treatment-specific articles and two RCTs. That's a solid foundation, but it's not the hundreds of studies that established conditions have. More independent replication will strengthen the case over time.

The ICD-10 coding gap matters, too, but not in the way people usually assume. A dedicated code would help. The bigger barrier for patients right now is reimbursement. CIRS visits are long and complex (initial appointments often run two hours), and standard insurance reimbursement rates don't cover that kind of time. That's why many CIRS-literate clinicians can't stay in business billing insurance and end up requiring cash pay. The coverage itself isn't usually the problem. The rates are.

Sample sizes in the early studies were small. The original RCT had 13 subjects. The brain imaging study had 91. These are statistically significant findings, but larger studies would add confidence. The 1,061-patient cohort from McMahon 2017 helps, and the field is trending toward larger samples.

And most CIRS research involves researchers connected to the original framework. Independent replication is growing. Harding at CUNY worked on the animal model. Bredesen and Gunn published in adjacent areas in 2016. Tuuminen's group in Finland has described a dampness-and-mold-hypersensitivity syndrome with significant symptomatic overlap (emphasizing neurological presentations) that mirrors much of the CIRS picture, even as biomarker definitions in that line of work are still developing. More truly independent research would strengthen the evidence base further.

So what's the actual question?

The "is CIRS real?" debate often gets framed as believers versus skeptics. That framing misses the point.

The loudest critics and the peer-reviewed researchers actually agree on what's junk science in the mold space: unvalidated urine tests, dubious at-home kits, influencer-driven diagnoses without clinical evaluation. We agree too.

The disagreement is about something those critics haven't addressed: the peer-reviewed clinical framework with RCTs, transcriptomic data, brain imaging, validated biomarkers, published case definitions, and independent replication. That evidence doesn't go away because wellness influencers also talk about mold.

The question isn't whether CIRS has evidence. The 2024 systematic review settled that. The question is why institutional recognition hasn't caught up to the published science. That's a question about medical sociology and funding priorities. Not about whether the transcriptomic fingerprint, the brain volume changes, or the biomarker patterns are lying.

"I struggled for years with chronic symptoms that other doctors wanted to give me band-aid solutions for, but with MoldCo, I actually got to the root cause. I have gone from being bedridden to feeling the best I ever have." MoldCo patient

Frequently asked questions

Does CIRS have an ICD-10 code?

Not a dedicated one yet. Most practicing clinicians bill under Z77.120, the code for contact with and suspected exposure to mold. This is more accurate than the older R65.10 (SIRS of non-infectious origin) and better describes what's being evaluated. The lack of a dedicated CIRS code is a coding infrastructure gap, not evidence that the condition doesn't exist. Many conditions were treated for years before receiving dedicated codes.

How is CIRS different from a mold allergy?

Mold allergy is an IgE-mediated response (the same pathway as pollen or dust allergies). CIRS involves innate immune dysfunction, a different arm of the immune system. The 3% mold allergy prevalence figure you might see cited is accurate for allergic response but doesn't apply to CIRS. About 24% of the population carries genetic susceptibility (HLA-DR/DQ haplotypes) for CIRS.

Can my regular doctor test for CIRS?

The CIRS biomarker panel (TGF-beta1, C4a, MMP-9, MSH, and others) is orderable through national laboratories like LabCorp. These aren't proprietary or fringe tests. However, most primary care doctors aren't trained to interpret them in the context of CIRS. If you want to explore whether mold-related illness might be contributing to your symptoms, MoldCo Care can help you work through the evaluation, if available in your state.

If the evidence is this strong, why don't more doctors know about it?

Medical education and institutional adoption lag behind published research. It typically takes around 17 years for research evidence to change clinical practice, with published ranges spanning roughly a decade to two decades. CIRS also faces a perception problem: the legitimate clinical research gets lumped in with wellness-industry misinformation about "toxic mold," making it easy for busy clinicians to dismiss.

Is the Shoemaker Protocol the only treatment?

According to the 2024 systematic review, it's the only treatment in the published literature with documented clinical efficacy. There's a documented evidence basis for each sequential step. MoldCo's approach is guided by this protocol.

Any health-related claims made on this site have not been evaluated by the Food and Drug Administration (FDA). The information provided on this site is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. MoldCo assumes no responsibility or liability for any errors or omissions in the content of the references, nor for any actions taken in reliance thereon.